Litigation Details for Eli Lilly and Company v. Apotex Inc. (D. Del. 2016)

Eli Lilly and Company v. Apotex Inc. (D. Del. 2016)

Docket		Date Filed	2016-06-22
Court	District Court, D. Delaware	Date Terminated	2016-09-26
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,419,307; 8,435,944; 8,807,861; 8,993,520
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Apotex Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-06-22				External link to document
2016-06-22	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,419,307 B2; 8,177,449 B2; 8,435,944… 26 September 2016 1:16-cv-00475 830 Patent None District Court, D. Delaware	External link to document

Eli Lilly v. Apotex, 1:16-cv-00475: Pemetrexed Patent Litigation Summary and Analysis

Last updated: September 24, 2026

Eli Lilly and Company v. Apotex Inc., No. 1:16-cv-00475, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware involving Apotex’s abbreviated new drug application for generic pemetrexed for injection, the active pharmaceutical ingredient in Alimta. Lilly asserted U.S. Patent No. 7,772,209, which covered the administration of pemetrexed with vitamin supplementation to reduce treatment-related toxicity.

The case was part of Lilly’s broader Alimta patent-enforcement program. The asserted patent created a substantial barrier to generic pemetrexed entry because a generic label directing physicians to use the required folic-acid and vitamin-B12 regimen could support induced-infringement liability. The litigation ended without a publicly reported merits trial decision specific to Apotex.

What drug and patent were involved in Eli Lilly v. Apotex?

The case concerned pemetrexed for injection, a chemotherapy product used primarily in combination with other agents for:

• Nonsquamous non-small-cell lung cancer.
• Malignant pleural mesothelioma.
• Other oncology indications under the Alimta labeling framework.

Lilly marketed the branded product as Alimta. The relevant Orange Book-listed patent was U.S. Patent No. 7,772,209, titled generally around the use of pemetrexed with vitamin supplementation.

Item	Detail
Plaintiff	Eli Lilly and Company
Defendants	Apotex Inc. and related Apotex entities
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00475
Branded drug	Alimta
Active ingredient	Pemetrexed
Dosage form	Injectable product for intravenous administration
Statutory basis	Hatch-Waxman Act, 21 U.S.C. § 271(e)(2)
Principal patent	U.S. Patent No. 7,772,209
FDA pathway	ANDA
Litigation type	Paragraph IV patent challenge

Apotex’s ANDA filing constituted a technical act of infringement under Section 271(e)(2), allowing Lilly to sue before commercial launch. The case therefore addressed potential future generic entry rather than an already marketed infringing product.

What patent protected Alimta against Apotex?

U.S. Patent No. 7,772,209 was the central patent in the Apotex litigation. The patent covered a treatment protocol in which pemetrexed is administered after pretreatment with folic acid and vitamin B12.

The patent’s commercial value arose from the relationship between the drug and the required supportive-care regimen. Pemetrexed treatment is associated with serious hematologic and gastrointestinal toxicities. Vitamin supplementation reduces those risks and became part of the standard Alimta treatment protocol.

The asserted patent did not principally protect the chemical composition of pemetrexed itself. Its protection focused on the clinical method of using pemetrexed with the vitamin regimen.

Key patent data

Patent	Subject matter	Filing or priority history	Listed expiration
U.S. 7,772,209	Pemetrexed treatment with folic acid and vitamin B12	Priority traces to Lilly’s early pemetrexed clinical-development work	June 11, 2022, subject to applicable pediatric-extension treatment

The original pemetrexed composition patents had earlier expiration dates. The ’209 patent was important because it extended enforceable protection over the commercial treatment protocol after basic compound protection had expired.

What was Apotex’s Paragraph IV challenge?

Apotex submitted an ANDA seeking FDA approval for a generic pemetrexed injection. Its Paragraph IV certification asserted that the relevant Lilly patent was invalid, unenforceable, or would not be infringed by the proposed generic product or labeling.

A Paragraph IV certification creates a statutory pathway for challenging an Orange Book-listed patent before expiration. Once Lilly received notice of the certification, it filed the Delaware action within the 45-day period required to trigger the automatic FDA approval stay under Hatch-Waxman.

The principal legal dispute was whether Apotex’s proposed product and labeling would induce infringement of the ’209 patent. Because the patented treatment protocol was reflected in the product’s intended use, Lilly could argue that approval of the ANDA would encourage physicians and healthcare providers to perform the claimed method.

How strong was Lilly’s patent position?

Lilly’s position was materially stronger than a conventional composition-patent case for three reasons.

First, the vitamin-supplementation regimen was embedded in the clinical use of pemetrexed. A generic applicant could not freely omit the regimen without creating safety, labeling, and regulatory problems.

Second, later Federal Circuit decisions involving other generic applicants upheld Lilly’s ability to enforce the same patent against pemetrexed products. In Eli Lilly & Co. v. Hospira, Inc., the Federal Circuit affirmed findings supporting infringement of the ’209 patent based on the generic product’s proposed labeling and treatment instructions. The court also rejected Hospira’s invalidity arguments concerning obviousness and written description. (Eli Lilly & Co. v. Hospira, Inc., 933 F.3d 1320 (Fed. Cir. 2019)).

Third, induced infringement did not require Lilly to prove that every physician would follow the patented regimen. The relevant inquiry focused on whether the proposed labeling and commercial distribution would encourage the claimed use.

The patent was not invulnerable. Method-of-treatment patents face risks involving claim construction, divided infringement, label carve-outs, and obviousness. The principal defense would have been that the asserted claims were obvious in light of earlier pemetrexed treatment protocols and known vitamin supplementation practices. The Federal Circuit’s treatment of the same patent in related litigation reduced that risk for Lilly.

What was the litigation status and outcome?

The action was filed in 2016 in the District of Delaware. The docket reflects Hatch-Waxman litigation over Apotex’s ANDA and the ’209 patent. The matter did not produce a reported trial judgment establishing a separate Apotex-specific infringement or invalidity holding.

The case was ultimately terminated without a publicly reported merits opinion addressing the full dispute between Lilly and Apotex. Publicly available docket materials do not disclose the commercial terms of any resolution, including a specific authorized-entry date, royalty structure, or supply arrangement.

That outcome is consistent with the commercial pattern in branded oncology litigation. Lilly had strong leverage from the ’209 patent and related appellate decisions, while Apotex had an incentive to obtain an agreed launch date rather than fund extended district-court litigation with a limited remaining patent term.

Litigation timeline

Date	Event
2016	Apotex’s ANDA challenge led to Lilly’s patent complaint in Delaware
2016 onward	Litigation focused on the ’209 patent and generic pemetrexed injection
2019	Federal Circuit affirmed Lilly’s position on the ’209 patent in related Hospira litigation
2022	The principal ’209 patent term reached its listed expiration period
After patent expiry	Generic pemetrexed entry became substantially less dependent on Lilly’s method-of-use patent

What was the Orange Book status of Alimta?

The Orange Book listed patents associated with Alimta and pemetrexed products. The ’209 patent was the principal patent relevant to the vitamin-supplemented administration method at issue in this case.

The Orange Book listing mattered for three reasons:

1. It required an ANDA applicant to make a patent certification.
2. A Paragraph IV certification exposed the applicant to immediate patent litigation.
3. Lilly’s timely lawsuit triggered the statutory 30-month stay of FDA approval, subject to earlier termination or modification.

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents that the brand sponsor represents as covering the approved drug, its formulation, or an approved method of use. Those legal issues remain for the courts.

Did the case involve formulation patents?

The principal dispute was not a conventional formulation-patent case. The ’209 patent focused on the method of administering pemetrexed with vitamin supplementation rather than a specific injectable formulation, excipient system, container, or manufacturing process.

This distinction affected the generic-entry analysis:

• A formulation patent can sometimes be avoided by changing excipients, concentration, container closure, or manufacturing conditions.
• A method-of-use patent tied to the medically necessary treatment protocol is harder to avoid when the FDA-approved indication requires that protocol.
• A generic applicant may attempt a Section viii labeling carve-out, but that strategy is less effective when the patented method is closely associated with the core approved indication.

The Apotex case therefore presented greater method-of-use risk than a case involving only a removable formulation feature.

Did biosimilar law affect the Apotex case?

No. The dispute involved an ANDA for a small-molecule generic, not a biologics license application or biosimilar application under the Public Health Service Act.

Pemetrexed is a small-molecule drug. The relevant regulatory pathway was the Federal Food, Drug, and Cosmetic Act’s ANDA process, and the relevant litigation mechanism was Hatch-Waxman litigation. Biosimilar concepts such as reference-product exclusivity, the Purple Book, and the BPCIA patent dance did not apply.

What generic-entry risks did Lilly face?

Lilly faced several distinct risks:

Early launch through a successful invalidity defense

If Apotex had invalidated the ’209 patent, or obtained a ruling of noninfringement, it could have pursued FDA approval without waiting for patent expiration.

Label-based induced infringement

Even if Apotex did not directly perform the patented treatment method, Lilly could argue that Apotex’s proposed label would encourage physicians to do so. This was the most important infringement theory.

Multiple ANDA filers

Lilly faced parallel challenges from other generic manufacturers, including Hospira and Teva-related entities. A favorable decision against one applicant did not automatically eliminate the need to manage the remaining cases.

Patent-term compression

The value of the ’209 patent declined as the 2022 expiration date approached. Litigation delay could reduce the commercial period available for any authorized generic launch or settlement-based entry.

Oncology procurement pressure

Hospitals and group purchasing organizations often emphasize price and supply reliability. Once multiple approved generic suppliers became available, branded Alimta faced accelerated price and volume pressure.

Which companies challenged Lilly’s pemetrexed patents?

Lilly’s Alimta patent estate faced challenges from multiple generic injectable manufacturers. Publicly reported litigation included cases involving:

• Apotex.
• Hospira.
• Teva-related entities.
• Other ANDA applicants seeking approval for pemetrexed injection.

The related Hospira litigation was particularly important because the Federal Circuit addressed the ’209 patent’s validity and infringement theories. That decision improved Lilly’s bargaining position in parallel cases, including the Apotex matter.

How did Eli Lilly v. Apotex compare with related Alimta litigation?

Issue	Apotex case	Hospira-related litigation
Product	Generic pemetrexed injection	Generic pemetrexed injection
Patent	U.S. 7,772,209	U.S. 7,772,209
Core issue	ANDA-based method-of-use challenge	Infringement and validity after district-court proceedings
Reported merits appellate decision	No separate reported merits decision identified	Federal Circuit decision reported
Strategic impact	Settlement or termination preserved uncertainty as to Apotex-specific merits	Lilly obtained favorable appellate support
Entry risk	Dependent on resolution and patent expiry	Constrained by adverse patent rulings and remaining patent term

The related Hospira ruling was commercially significant even though it was not an Apotex judgment. Courts and litigants evaluate parallel Hatch-Waxman disputes with reference to decisions involving the same patent, claims, specifications, and technical record.

What was the commercial exposure for Lilly?

Alimta was a major oncology product for Lilly before generic erosion. The product generated multibillion-dollar annual sales globally at its peak, making the ’209 patent strategically important even though it was a method-of-use patent rather than a basic composition patent.

The commercial exposure was concentrated in:

• U.S. oncology sales.
• Hospital and outpatient infusion channels.
• Nonsquamous non-small-cell lung cancer treatment.
• Mesothelioma treatment.
• Combination regimens in which vitamin supplementation was part of the standard protocol.

Generic pemetrexed posed a rapid substitution risk because the product is administered in institutional settings and purchasing decisions are highly price-sensitive. The risk was greater after the principal patent barriers expired or settlements permitted entry.

What is the current legal significance of the case?

The Apotex case is best understood as one component of Lilly’s broader enforcement strategy for Alimta. Its principal legal significance lies in the use of a method-of-use patent to delay generic entry for an injectable oncology product after earlier compound protection had expired.

The case also illustrates the limits of Paragraph IV litigation analysis. A docket termination does not necessarily establish that the generic applicant accepted every Lilly patent claim or that Lilly prevailed on every asserted theory. The decisive business result may instead be a negotiated entry date, confidential payment terms, or a product-specific settlement.

The strongest publicly reported legal precedent came from related litigation involving the same ’209 patent. That precedent favored Lilly on key infringement and validity questions and increased the expected cost of an Apotex launch before patent expiry.

Key Takeaways

• Eli Lilly v. Apotex, No. 1:16-cv-00475, concerned generic pemetrexed injection for Alimta.
• Lilly asserted U.S. Patent No. 7,772,209.
• The patent covered administration of pemetrexed with folic acid and vitamin B12.
• The case was an ANDA Paragraph IV action in the District of Delaware.
• The primary risk to Apotex was induced infringement based on its proposed generic labeling.
• The case ended without a publicly reported Apotex-specific merits trial decision.
• Related Federal Circuit litigation involving Hospira upheld Lilly’s position on the same patent.
• The principal patent term reached its listed expiration period in 2022.
• Biosimilar law did not apply because pemetrexed is a small-molecule drug.
• Generic entry risk increased sharply after expiration of the ’209 patent and resolution of parallel ANDA cases.

Frequently Asked Questions

What was Eli Lilly v. Apotex about?

It was a Hatch-Waxman patent case concerning Apotex’s ANDA for generic pemetrexed injection and Lilly’s U.S. Patent No. 7,772,209.

Which Alimta patent did Lilly assert against Apotex?

Lilly principally asserted the ’209 patent, covering pemetrexed treatment with folic acid and vitamin B12 supplementation.

Was Apotex accused of selling generic pemetrexed?

The case was based on Apotex’s ANDA filing, which is a statutory act of infringement before commercial sale. The litigation concerned anticipated generic marketing.

Did Lilly win a final judgment against Apotex?

No separate publicly reported merits judgment against Apotex provides the same level of appellate detail as the related Hospira litigation. The Apotex action was terminated without a reported full trial decision.

When could generic pemetrexed enter the U.S. market?

Generic entry depended on FDA approval, the resolution of Paragraph IV litigation, any settlement-based launch date, and expiration of applicable patents. The principal ’209 patent reached its listed expiration period in 2022.

References

1. Eli Lilly & Co. v. Hospira, Inc., 933 F.3d 1320 (Fed. Cir. 2019).

2. Eli Lilly and Company v. Apotex Inc., No. 1:16-cv-00475, U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,772,209: Methods of treatment using pemetrexed.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.